Ignite Creation Date:
2025-12-26 @ 11:13 PM
Ignite Modification Date:
2026-03-15 @ 6:59 AM
Study NCT ID:
NCT05885412
Status:
RECRUITING
Last Update Posted:
2024-10-04
First Post:
2023-05-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Sponsor:
Rocket Pharmaceuticals Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Arrhythmogenic cardiomyopathy | View |
| None | Arrhythmogenic Right Ventricular Cardiomyopathy | View |
| None | Arrhythmogenic Right Ventricular Dysplasia | View |
| None | Sudden Cardiac Death | View |
| None | Genetic cardiomyopathy | View |
| None | Gene therapy | View |
| None | PKP2 | View |
| None | ARVC | View |
| None | ARVD | View |
| None | ACM | View |
| None | Cardiac Arrest | View |
| None | Ventricular Arrhythmia | View |